MedicQuant develops a point-of-care diagnostic device that utilizes a novel chip technology to measure Direct Oral Anticoagulants (DOACs) directly from whole blood in under 10 minutes. This solution addresses the lack of readily available testing for anticoagulant levels in emergency settings, enhancing patient care through rapid and accurate results.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Currently, there are no readily available point-of-care solutions to rapidly measure Direct Oral Anticoagulant (DOAC) levels in patients, particularly in emergency settings. The lack of immediate DOAC level information can hinder timely and appropriate treatment decisions.
Solution
MedicQuant is developing a point-of-care diagnostic device that enables rapid measurement of DOAC levels directly from whole blood samples. Utilizing a novel chip technology, the device provides results in under 10 minutes, eliminating the need for sample preparation. This allows healthcare providers to quickly assess anticoagulant levels and make informed treatment decisions at the patient's bedside, improving patient care and outcomes. The device's compact size makes it suitable for use in various settings, including emergency rooms and hospital departments.
Target Audience
The primary target audience includes hospitals, emergency rooms, and other healthcare providers who require rapid and accurate DOAC level measurements for patient management.
Features
- Novel chip technology for direct DOAC measurement from whole blood
- Rapid results in under 10 minutes
- Point-of-care testing, suitable for emergency rooms and hospital departments
- Simple operation with no sample preparation required
- Compact device size for easy portability and use in various settings